Książki

A comprehensive resource for drug discovery and pharmaceutical research The Wiley Handbook of Current and Emerging Drug Therapies brings together, for the first time in a single resource, the most current information on drug discovery and pharmaceutical research. Within every major therapeutic area, and for over sixty diseases and indications, the Handbook provides: * A detailed etiological and pathophysiological overview * A comprehensive analysis of currently approved drugs targeting these diseases * Product by product analyses of drugs currently in development * Authoritative essays on key topics * Detailed, market-oriented analyses of emerging technologies and business opportunities Volumes 1- 4 * Immune System * Infectious Diseases * Metabolic Disorders * Oncology * Emerging Technologies and Markets Volumes 5- 8 * Cardiology * Central Nervous System * Gastrointestinal * Genitourinary * Ophthalmologic * Pain Treatment * Respiratory * Emerging Technologies and Markets Also available in a regularly updated online version--visit www.interscience.wiley.com/mrw/cedt for more details

Wiley Handbook of Current and Emerging Drug Therapies, 4 Vols.

PART I: INTRODUCTION.

The Drug Discovery Process.

Clinical Trials, Overview.

Therapeutic Area Trends in R&D of the Top 20 Pharmaceutical Companies.

PART II: ONCOLOGY.

Aggressive Non-Hodgkin's Lymphomas.

Bladder Cancer.

Breast Cancer.

Cervical Cancer.

Chronic Lymphocytic Leukemia (CLL).

Chronic Myelogenous Leukemia.

Colorectal Cancer.

Malignant Melanoma.

Multiple Myeloma.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 2.

PART II: ONCOLOGY.

Non-Small-Cell Lung Cancer.

Ovarian Cancer.

Pancreatic Cancer.

Prostate Cancer.

Small-Cell Lung Cancer.

PART III: IMMUNE SYSTEM.

Allergic Rhinitis.

Asthma.

Crohn's Disease.

Psoriasis.

Rheumatoid Arthritis.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 3.

PART IV. METABOLIC DISEASES.

Diabetic Retinopathy.

Dyslipidemia.

Metabolic Syndrome.

Obesity.

Osteoporosis.

Type 1 Diabetes.

Type 2 Diabetes.

PART V. INFECTIOUS DISEASES.

Acute Exacerbations of Chronic Bronchitis.

Community-Acquired Pneumonia.

Complicated Skin and Soft Tissue Infections.

Hepatitis C.

Methicillin-Resistant Staphylococcus Aureus.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 4.

PART VI. EMERGING TECHNOLOGIES AND BUSINESS OPPORTUNITIES.

Data and Information Integration in Pharmaceutical R&D.

Impact of Technological Advances on Pharmaceutical Productivity.

Advances in Medicinal Chemistry and Lead Optimization.

Bio-Defense Opportunities in the Biotechnology and Pharmaceutical Industries.

Fear of Theranostics: Why an Industry Has Not Really Emerged.

Beyond Commodity Drugs: Strategic Diversification in the Generics Industry.

PART VII: GLOBAL MARKETS AND NATIONAL POLICY.

The EU Clinical Trials Directive: Impact in Europe and Beyond.

The Indian Pharmaceutical Industry in Transition: Changes and Opportunities Ahead.

Spotlight on the Australian and New Zealand Pharmaceutical and Biotechnology Industries.

Overview of the World's Major OTC Markets.

Biotech Hubs-Key Growth Engines for Drug Development.

Pharmaceutical Marketplace in Central and Eastern Europe.

Valuation Models for European Biotech.

Taking Global Action: Integrating Social Responsibility into Corporate Practices.

Global Branding Strategy: From the Blockbuster to the Targeted Model.

PART VIII: NEW OPPORTUNITIES IN DRUG DISCOVERY AND PIPELINE DEVELOPMENT.

Prospects for Genomics-Derived Drugs: New Approaches and Impact on Pharmaceutical Pipelines.

Prying Open the Pipeline: Drug Discovery and Development in the Postgenomics Era.

Glycomics: The Impact of Carbohydrates on Biological Function and the Implications for Drug Discovery.

High-Content Screening for Drug Discovery and Target Validation.

High-Throughput ADMET Screening: Improving the Efficiency of Drug Discovery.

Emerging Concepts in GPCR Research and Their Implications for Drug Discovery.

Optimizing Knowledge Management in Pharmaceutical Companies.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Cumulative Subject Index, Volumes 1-4.